Explore the words cloud of the PRELICAN project. It provides you a very rough idea of what is the project "PRELICAN" about.
The following table provides information about the project.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
|Coordinator Country||France [FR]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-06-01 to 2018-11-30|
Take a look of project's partnership.
|1||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||coordinator||150˙000.00|
Advanced liver disease and cancer is the only major cause of death still increasing each year. Major causes include hepatitis B and C viruses, alcohol and non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). A major contributing factor to the increasing incidence and mortality of liver disease is the staggering rise in obesity. The absence of effective therapeutic options for NAFLD/NASH, advanced liver disease and cancer contribute to the poor prognosis and the high cost associated with patient care. We have established a tractable and clinically relevant human cell-based model system in which viral infection, ethanol or free fatty acids induce a clinical gene expression signature robustly predicting liver disease progression and long-term HCC risk in cirrhotic patients. Using this model we identified compounds as HCC chemopreventive agents. Aiming to evaluate these compounds for future clinical development and potential commercialization we will perform proof-of-concept studies in state-of-the-art mouse models for NASH and hepatocarcinogenesis. Specifically we will assess the therapeutic effect on liver inflammation, steatosis, fibrosis and HCC development and investigate its safety in long-term administration. With the completion of this program we expect to obtain a robust proof-of-concept data package as a first- or best-in-class compound for treatment of chronic liver disease and prevention of HCC.
|year||authors and title||journal||last update|
Mirjam B Zeisel, Punita Dhawan, Thomas F Baumert
Tight junction proteins in gastrointestinal and liver disease
published pages: gutjnl-2018-3169, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2018-316906
Armando Andres Roca Suarez, Thomas F. Baumert, Joachim Lupberger
Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling
published pages: 564-566, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2018.05.033
|Journal of Hepatology 69/3||2019-05-16|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRELICAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRELICAN" are provided by the European Opendata Portal: CORDIS opendata.
High throughput multiplexed trace-analyte screening for diagnostics applicationsRead More
Broadband Quantum-Limited Parametric Amplifier for Astronomy and Quantum Information TechnologyRead More
The Mass Politics of DisintegrationRead More